BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LB-102 (methylated amisulpride) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LB-102 (methylated amisulpride)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07363577-840@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:LB-102 (methylated amisulpride): Phase 3 readout est. (NCT07363577)
DESCRIPTION:LB-102 (methylated amisulpride)\, phase 3\, Schizophrenia.\nStu
 dy: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acut
 e Schizophrenia\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07363577
URL:https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494305-840@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:LB-102 (methylated amisulpride): Phase 2 readout est. (NCT07494305)
DESCRIPTION:LB-102 (methylated amisulpride)\, phase 2.\nStudy: Multicenter 
 Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adul
 t Patients With BP1MDE.\nEstimated primary completion: February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lb-102-methylated-amisulp
 ride#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07494305
URL:https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369154-840@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:LB-102 (methylated amisulpride): Phase 3 readout est. (NCT07369154)
DESCRIPTION:LB-102 (methylated amisulpride)\, phase 3\, Schizophrenia.\nStu
 dy: 52-week Open Label Safety-Tolerability Study\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lb-102-methylated-amisulpride#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07369154
URL:https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
